Molina Healthcare (MOH) shares were recently steady at around US$178, giving the managed care company a market value near US$9.3b as investors weigh its role in Medicaid, Medicare and marketplace insurance plans.

Recent trading has been choppy, with a 15.6% 90 day share price return contrasting with a 1 year total shareholder return that has declined 41.4%. This suggests that recent momentum has not yet repaired longer term losses.

If you want to see how other healthcare related ideas are shaping up, it could be a good time to widen your watchlist with 35 healthcare AI stocks

With the stock sitting just below analysts’ price target and trading after a steep multi year decline, the key question is whether Molina appears undervalued today or whether the market is already accounting for potential future growth.

Most Popular Narrative: 56.8% Undervalued

At a last close of $178.02 against a narrative fair value of $411.65, the current price sits well below what this widely followed view implies.

• Membership Growth: MOH has seen a 9% increase in members year over year, reaching approximately 5.7 million members as of March 31, 2024. This growth is driven by new contract wins, acquisitions, and expansion.

Want to see what kind of premium revenue curve and profit margin path could underpin that valuation? The narrative leans on compound membership gains and expanding government program exposure to justify its cash flow outlook.

Result: Fair Value of $411.65 (UNDERVALUED)

However, this hinges on manageable medical costs and a stable regulatory backdrop, particularly regarding Medicaid redeterminations, which have scope to pressure revenue and membership.

Another View: Earnings Multiple Sends A Caution Flag

While both the user narrative and our cash flow model point to undervaluation, the current P/E of 49.3x is much higher than the US Healthcare industry at 23.9x and above the 42x fair ratio. That gap can mean valuation risk if sentiment or earnings expectations reset.

Before you lean too heavily on any single lens, it can help to see what the numbers imply when priced against earnings as well as cash flows. This is where the detailed valuation breakdown steps in, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of caution and optimism in the story so far, it makes sense to move quickly, review the data for yourself, and weigh both sides with 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop here, you risk missing other stocks that might suit your goals, so take a moment to scan a few focused ideas from the Simply Wall Street Screener.

• Target potential mispricings by scanning 46 high quality undervalued stocks that combine solid fundamentals with room for the market to reassess expectations.
• Prioritise resilience by reviewing 64 resilient stocks with low risk scores where balance sheets, earnings quality, and volatility profiles aim to keep surprises to a minimum.
• Spot underfollowed opportunities by checking the screener containing 22 high quality undiscovered gems that may sit off the radar yet still meet strict financial quality filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.